Literature DB >> 10025591

Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients.

M J Schwarz1, M Späth, H Müller-Bardorff, D E Pongratz, B Bondy, M Ackenheil.   

Abstract

The serotonergic system has repeatedly been discussed to be involved in the pathophysiology of fibromyalgia (FM), which is a syndrome of widespread pain and sleep disturbance. Elevated levels of substance P (SP), a mediator of nociception, have been described in FM. In this study the possible relationship between SP and serotonin (5-HT) together with its precursor tryptophan (TRP) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) was evaluated in 51 serum samples of fibromyalgia patients. These parameters were compared with clinical data such as pain intensity or sleep quality. A strong negative correlation between SP and 5-HIAA (P = .000) as well as between SP and TRP (P = .009) could be demonstrated. High serum concentrations of 5-HIAA and TRP showed a significant relation to low pain scores (5-HIAA: P = .030; TRP: P = .014). Moreover, 5-HIAA was strongly related to good quality of sleep (P = .000), while SP was related to sleep disturbance (P = .005). These data are valid to support the hypothesis of a systemic involvement of 5-HT and SP in fibromyalgia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025591     DOI: 10.1016/s0304-3940(98)00937-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  23 in total

Review 1.  Neuropharmacologic targets and agents in fibromyalgia.

Authors:  Rie Suzuki; Anthony H Dickenson
Journal:  Curr Pain Headache Rep       Date:  2002-08

Review 2.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol
Journal:  Rheumatol Int       Date:  2005-11-20       Impact factor: 2.631

3.  Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?

Authors:  Georgios Papadokostakis; Pavlos Katonis; John Damilakis; Alexander Hadjipavlou
Journal:  Eur Spine J       Date:  2005-04-15       Impact factor: 3.134

4.  Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia.

Authors:  Lisete Haas; Luis V C Portela; Ana Elisa Böhmer; Jean Pierre Oses; Diogo R Lara
Journal:  Neurochem Res       Date:  2010-05       Impact factor: 3.996

Review 5.  Is fibromyalgia a distinct clinical syndrome?

Authors:  C L Rau; I J Russell
Journal:  Curr Rev Pain       Date:  2000

Review 6.  Fibromyalgia and sleep in animal models: a current overview and future directions.

Authors:  Cristina Frange; Camila Hirotsu; Helena Hachul; Paula Araujo; Sergio Tufik; Monica L Andersen
Journal:  Curr Pain Headache Rep       Date:  2014

7.  Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.

Authors:  Amanda M Brandow; Nancy J Wandersee; Mahua Dasgupta; Raymond G Hoffmann; Cheryl A Hillery; Cheryl L Stucky; Julie A Panepinto
Journal:  Br J Haematol       Date:  2016-08-19       Impact factor: 6.998

8.  Non-invasive brain stimulation approaches to fibromyalgia pain.

Authors:  Baron Short; Jeffrey J Borckardt; Mark George; Will Beam; Scott T Reeves
Journal:  J Pain Manag       Date:  2009-01-01

9.  Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients.

Authors:  Bernd Frank; Beate Niesler; Brigitta Bondy; Michael Späth; Dieter E Pongratz; Manfred Ackenheil; Christine Fischer; Gudrun Rappold
Journal:  Clin Rheumatol       Date:  2004-05-07       Impact factor: 2.980

Review 10.  Neurobiology of fibromyalgia and chronic widespread pain.

Authors:  Kathleen A Sluka; Daniel J Clauw
Journal:  Neuroscience       Date:  2016-06-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.